TPIAO Special Precautions

For specific person with idiosyncrasy, the platelet count might increase in excess when the TPIAO is administered, so it should be under direct medical supervision in 3A hospital.
TPIAO is suitable for chemotherapy-induced thrombocytopenia in cancer patients with solid tumours. TPIAO therapy is recommended to patients with the platelet level lower than 50x10⁹/L or physicians considered it necessary to increase the level of platelet.
For the patients with chemotherapy-induced thrombocytopenia in solid tumours, TPIAO shall be given in 6 to 24 hours after chemotherapy.
During TPIAO therapy, the periodic routine blood test should be performed, generally once every other day, to monitor the changes of peripheral platelet count. If platelet count reaches the target level, TPIAO should be stopped. Routine blood tests should be monitored (including platelet count and peripheral blood smear) before, during and after TPIAO therapy. Peripheral blood classification should be tested to establish the baselines of RBC&WBC morphologic abnormality before TPIAO therapy. Periodic routine blood test (including platelet count and peripheral blood smear) should be performed before TPIAO therapy and in 2 weeks at least after withdrawal.